EP Patent

EP3372592A1 — Solid forms of lesinurad amine salts

Assigned to Zentiva KS · Expires 2018-09-12 · 8y expired

What this patent protects

The invention provides solid forms of lesinurad with an amino group-containing organic base of formula         R 1 -NH-R 2 , wherein the R 1 and R 2 groups are independently selected from the group consisting of -C(=O)-NH 2 , hydrogen, a linear or branched C1-C6 alkyl or …

USPTO Abstract

The invention provides solid forms of lesinurad with an amino group-containing organic base of formula         R 1 -NH-R 2 , wherein the R 1 and R 2 groups are independently selected from the group consisting of -C(=O)-NH 2 , hydrogen, a linear or branched C1-C6 alkyl or C1-C6 cycloalkyl while the alkyl or cycloalkyl are optionally substituted by at least one hydroxy group, provided that at least one of the R 1 and R 2 groups is not hydrogen. Further, an amorphous and crystalline form of lesinurad free acid are disclosed. Methods of production and medical uses of the solid forms of lesinurad are also provided by the present invention.

Drugs covered by this patent

Patent Metadata

Patent number
EP3372592A1
Jurisdiction
EP
Classification
—
Expires
2018-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Zentiva KS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.